位置:成果数据库 > 期刊 > 期刊详情页
Rapamycin in fibrotic diseases: beneficial or detrimental agent?
  • 期刊名称:Chin Med J
  • 时间:0
  • 页码:0-0
  • 分类:TQ465.5[化学工程—制药化工] Q516[生物学—生物化学]
  • 作者机构:[1]Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China, [2]Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Institute of Respiratory Medicine, Beijing 100020, China
  • 相关基金:This work was supported by grants from National Natural Science Foundation of China (No. 30971312) and the Key Project of Beijing Municipal Education Commission Sci-Tech Development Program (No. KZ201110025028).
  • 相关项目:肺纤维化过程中mTOR途径的激活与雷帕霉素的抗纤维化作用
中文摘要:

Rapamycin was first isolated from a strain of Streptomyces hygroscopicus in the early 1970s from a soil sample taken on Easter Island.1 Because the antiproliferative effects of rapamycin on yeast cell,as well as B and T lymphocytes,it was first identified as an antimicrobial agent with potent immunosuppressive activity and has been used in antirejection therapy.2,3The discovery of rapamycin led to the identification and clone of the mammalian target of rapaymycin (mTOR).mTOR is a highly conserved serine-threonine kinase shown to integrate and coordinate diverse signaling pathway mediated by growth factors,nutrient availability and energy status to play a critical role in cell growth,proliferation,division,migration,and survival.4Structurally,mTOR is a part of two signaling complexes,mTOR complex 1 (mTORC1) and mTORC2.

英文摘要:

apamvcin was first isolated from a strain of Sreptomyces hygroscopicus in the early 1970s froma soil sample taken on Easter Island. Because the antiproliferative effects of rapamycin on yeast cell, as well as B and T lymphocytes, it was first identified as an antimicrobial agent with potent immunosuppressive activity and has been used in antirejection therapy.

同期刊论文项目
同项目期刊论文